OBJECTIVE: The objective was to determine the safety and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD). SUMMARY AND BACKGROUND DATA: PNALD can be a lethal complication in children with short bowel syndrome (SBS). ILE based on soybean oil administered with parenteral nutrition (PN) may contribute to its etiology. METHODS: We performed an open-labeled trial of a fish oil-based ILE in 42 infants with SBS who developed cholestasis (serum direct bilirubin >2 mg/dL) while receiving soybean oil-based ILE. Safety and efficacy outcomes were compared with those from a contemporary cohort of 49 infants with SBS and cholestasis whose PN course included soybean ILE only. The primary efficacy end-point was time to reversal of cholestasis (direct bilirubin <=2 mg/dL). RESULTS: Three deaths and 1 liver transplantation occurred in the fish oil cohort, compared with 12 deaths and 6 transplants in the soybean oil cohort (P = 0.005). Among survivors not transplanted during PN, cholestasis reversed while receiving PN in 19 of 38 patients in the fish oil cohort versus 2 of 36 patients in the soybean oil cohort. Based on Cox models, subjects receiving fish oil-based ILE experienced reversal of cholestasis 6 times faster (95% CI: 2.0-37.3) than those receiving soybean oil-based ILE. The provision of fish oil-based ILE was not associated with hypertriglyceridemia, coagulopathy, or essential fatty acid deficiency. Moreover, hypertriglyceridemic events and abnormal international normalized ratio levels were more common among controls. CONCLUSIONS: Fish oil-based ILE is safe, may be effective in treating PNALD, and may reduce mortality and organ transplantation rates in children with SBS.
OBJECTIVE: The objective was to determine the safety and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD). SUMMARY AND BACKGROUND DATA: PNALD can be a lethal complication in children with short bowel syndrome (SBS). ILE based on soybeanoil administered with parenteral nutrition (PN) may contribute to its etiology. METHODS: We performed an open-labeled trial of a fish oil-based ILE in 42 infants with SBS who developed cholestasis (serum direct bilirubin >2 mg/dL) while receiving soybeanoil-based ILE. Safety and efficacy outcomes were compared with those from a contemporary cohort of 49 infants with SBS and cholestasis whose PN course included soybean ILE only. The primary efficacy end-point was time to reversal of cholestasis (direct bilirubin <=2 mg/dL). RESULTS: Three deaths and 1 liver transplantation occurred in the fish oil cohort, compared with 12 deaths and 6 transplants in the soybeanoil cohort (P = 0.005). Among survivors not transplanted during PN, cholestasis reversed while receiving PN in 19 of 38 patients in the fish oil cohort versus 2 of 36 patients in the soybeanoil cohort. Based on Cox models, subjects receiving fish oil-based ILE experienced reversal of cholestasis 6 times faster (95% CI: 2.0-37.3) than those receiving soybeanoil-based ILE. The provision of fish oil-based ILE was not associated with hypertriglyceridemia, coagulopathy, or essential fatty acid deficiency. Moreover, hypertriglyceridemic events and abnormal international normalized ratio levels were more common among controls. CONCLUSIONS: Fish oil-based ILE is safe, may be effective in treating PNALD, and may reduce mortality and organ transplantation rates in children with SBS.
Authors: V Colomb; A Jobert-Giraud; F Lacaille; O Goulet; J C Fournet; C Ricour Journal: JPEN J Parenter Enteral Nutr Date: 2000 Nov-Dec Impact factor: 4.016
Authors: O Zamir; M S Nussbaum; S Bhadra; M T Subbiah; J F Rafferty; J E Fischer Journal: JPEN J Parenter Enteral Nutr Date: 1994 Jan-Feb Impact factor: 4.016
Authors: Lee Call; Tiffany Molina; Barbara Stoll; Greg Guthrie; Shaji Chacko; Jogchum Plat; Jason Robinson; Sen Lin; Caitlin Vonderohe; Mahmoud Mohammad; Dennis Kunichoff; Stephanie Cruz; Patricio Lau; Muralidhar Premkumar; Jon Nielsen; Zhengfeng Fang; Oluyinka Olutoye; Thomas Thymann; Robert Britton; Per Sangild; Douglas Burrin Journal: J Lipid Res Date: 2020-04-29 Impact factor: 5.922
Authors: Bram P Raphael; Paul D Mitchell; Darryl Finkton; Hongyu Jiang; Tom Jaksic; Christopher Duggan Journal: J Pediatr Date: 2015-04-01 Impact factor: 4.406
Authors: Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff Journal: Clin Nutr Date: 2019-01-16 Impact factor: 7.324
Authors: Meredith A Baker; Bennet S Cho; Lorenzo Anez-Bustillos; Duy T Dao; Amy Pan; Alison A O'Loughlin; Zachary M Lans; Paul D Mitchell; Vania Nosé; Kathleen M Gura; Mark Puder; Gillian L Fell Journal: Am J Clin Nutr Date: 2019-04-01 Impact factor: 7.045
Authors: Brian T Kalish; Hau D Le; Jonathan M Fitzgerald; Samantha Wang; Kyle Seamon; Kathleen M Gura; Karsten Gronert; Mark Puder Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-10-03 Impact factor: 4.052
Authors: Patrick M Chesley; Sabrina E Sanchez; Lilah Melzer; Assaf P Oron; Simon P Horslen; F Curt Bennett; Patrick J Javid Journal: J Pediatr Gastroenterol Nutr Date: 2016-07 Impact factor: 2.839